Please login to the form below

Not currently logged in
Email:
Password:

risdiplam

This page shows the latest risdiplam news and features for those working in and with pharma, biotech and healthcare.

Genentech’s Evrysdi gets extended FDA approval for spinal muscular atrophy

Genentech’s Evrysdi gets extended FDA approval for spinal muscular atrophy

Genentech’s Evrysdi (risdiplam), a treatment for spinal muscular atrophy (SMA), has been given an extended approved by the US Food and Drug Administration (FDA) to include babies under two months

Latest news

More from news
Approximately 6 fully matching, plus 22 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
The Difference Collective

Welcome to the Difference Collective – a healthcare communications team of 80+ talented experts who Deliver Differently. We’re purpose-built around...

Latest intelligence

Early communications in Pharma: How effective pre-approval comms delivers launch success
What communications are required for a successful launch...
Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...